Takeda Pharmaceutical (TAK) Equity Average: 2019-2025

  • Takeda Pharmaceutical's Equity Average fell 2.65% to $47.3 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $47.3 billion, marking a year-over-year decrease of 2.65%. This contributed to the annual value of $48.0 billion for FY2025, which is 1.54% down from last year.
  • As of Q1 2025, Takeda Pharmaceutical's Equity Average stood at $47.3 billion, which was down 2.65% from $48.6 billion recorded in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Equity Average peaked at $48.9 billion during Q1 2022, and registered a low of $46.2 billion during Q1 2021.
  • Its 3-year average for Equity Average is $48.1 billion, with a median of $48.5 billion in 2023.
  • Per our database at Business Quant, Takeda Pharmaceutical's Equity Average grew by 5.96% in 2022 and then fell by 2.65% in 2025.
  • Takeda Pharmaceutical's Equity Average (Quarterly) stood at $46.2 billion in 2021, then climbed by 5.96% to $48.9 billion in 2022, then fell by 0.89% to $48.5 billion in 2023, then rose by 0.16% to $48.6 billion in 2024, then dropped by 2.65% to $47.3 billion in 2025.
  • Its Equity Average was $47.3 billion in Q1 2025, compared to $48.6 billion in Q1 2024 and $48.5 billion in Q1 2023.